Taysha Gene Therapies Inc
NASDAQ:TSHA

Watchlist Manager
Taysha Gene Therapies Inc Logo
Taysha Gene Therapies Inc
NASDAQ:TSHA
Watchlist
Price: 1.72 USD Market Closed
Market Cap: 352.5m USD

Profitability Summary

35/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Taysha Gene Therapies Inc

Revenue
8.3m USD
Operating Expenses
-95m USD
Operating Income
-86.6m USD
Other Expenses
-2.7m USD
Net Income
-89.3m USD

Margins Comparison
Taysha Gene Therapies Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
352.5m USD
-1 039%
-1 072%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
-21 040%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
29%
8%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
22%
12%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
38%
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
40%
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
-392%
AU
CSL Ltd
ASX:CSL
121.1B AUD
26%
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
30%
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
-33%
NL
argenx SE
XBRU:ARGX
32.9B EUR
-1%
38%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Taysha Gene Therapies Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
US
Taysha Gene Therapies Inc
NASDAQ:TSHA
352.5m USD
-122%
-54%
-64%
-431%
FR
Pharnext SCA
OTC:PNEXF
6T USD
115%
-391%
275%
3 093%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
62%
3%
17%
20%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
68%
4%
10%
10%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
2%
1%
22%
15%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
-3%
-2%
23%
-102%
US
Epizyme Inc
F:EPE
94.1B EUR
-877%
-67%
-73%
-182%
AU
CSL Ltd
ASX:CSL
121.1B AUD
15%
7%
12%
9%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
16%
12%
13%
65%
US
Seagen Inc
F:SGT
39.3B EUR
-28%
-21%
-27%
-39%
NL
argenx SE
XBRU:ARGX
32.9B EUR
20%
18%
0%
-11%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.